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Objectives: To determine the temporal relationship between antibiotic use and incidence of antibiotic-resistant
Escherichia coli in both the inpatient and outpatient setting of a large urban area.
Methods: A retrospective observational time-series analysis was performed to evaluate the incidence of non-
duplicate clinical isolates of E. coli resistant to ciprofloxacin, trimethoprim/sulfamethoxazole and cefepime from
January 2000 through December 2007, combined with a transfer function model of aggregated data on anti-
biotic use in both settings obtained from the hospital’s pharmacy and outpatient billing offices.
Results: Ciprofloxacin resistance increased from 6.0% (2000) to 15.4% (2007; P ,0.0001) and cefepime resist-
ance from 0.9% (2002) to 3.2% (2007; P¼ 0.01). Trimethoprim/sulfamethoxazole resistance remained stable
(23.7%–25.8%). Total antibiotic use increased in both settings, while fluoroquinolone use increased signifi-
cantly only among outpatients. A temporal effect between fluoroquinolone resistance in community E. coli iso-
lates and outpatient use of ciprofloxacin (immediate effect and time lag 1 month) and moxifloxacin (time lag
4 months) was observed, explaining 51% of the variance over time. The incidence of cefepime resistance in
E. coliwas correlated with ciprofloxacin use in the inpatient (lag 1 month) and outpatient (lag 4 months) settings
and with the use of ceftriaxone (lag 0 month), piperacillin/tazobactam (3 months) and cefepime (3 months) in
the hospital (R2¼ 51%).
Conclusions: These results support efforts to reduce prescribing of fluoroquinolones for control of resistant E. coli
including extended-spectrum b-lactamase producers and show the added value of time-series analysis to
better understand the interaction between community and hospital antibiotic prescribing and its spill-over
effect on antibiotic resistance.
Keywords: antibiotic resistance, E. coli, fluoroquinolone resistance, extended-spectrum b-lactamase-producing bacteria, transfer
function model, health policy making, time-series analysis
Introduction
Switzerland is known as a country with a low level of antibiotic
use in the outpatient setting.1,2 Nevertheless, there seems to
be a relative overuse of fluoroquinolones, compared with other
European countries.1 According to the Swiss resistance surveil-
lance network, fluoroquinolone resistance in clinical isolates of
Escherichia coli was 15.9% in 2008, which is similar to countries
like Belgium and France that have much higher overall antibiotic
use.3,4 This finding is not surprising since a link between
fluoroquinolone use and resistance to this antimicrobial class
has been described in E. coli isolates from the inpatient as well
as the outpatient setting on both an ecological and an individual
patient level.5–8 Similar evidence has been reported for the link
between use of certain antibiotics and the rate of extended-
spectrum b-lactamase (ESBL)-producing Enterobacteriaceae.8,9
Hitherto, most studies linking antibiotic use to antibiotic resist-
ance have focused on either the outpatient or the inpatient setting
as if these were completely separate entities. This separation is,
however, artificial since antibiotic resistance is imported from
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the community into the hospital and vice versa. Thus, antibiotic
use in one setting is likely to impact antibiotic resistance in the
other.10 The particular healthcare structure in the Swiss canton
of Geneva offers a unique opportunity to analyse in parallel the
association between antibiotic use and resistance in E. coli using
data fromboth the community and the onlymajor public hospital.
The objective of this study was to determine the time-varying
effect of antibiotic use on the incidence of antibiotic-resistant
E. coli in both the inpatient and outpatient setting of this large
urban area in Switzerland.
Methods
Setting
In the Swiss canton of Geneva with a population of 450000 inhabitants
there is only one major public hospital, providing both primary and ter-
tiary care. The University of Geneva Hospitals (HUG) is a 2200 bed health-
care centre with 45000 admissions and .850000 outpatient visits
each year. Outpatient prescriptions in the canton are systematically
recorded by the major invoicing office of the Swiss pharmacists’ organiz-
ation (OFAC, Geneva, Switzerland). Figure 1 summarizes important infor-
mation about the study population, definitions and policies implemented
during the study period.
Antibiotic use
During the study period, no institutional policy regarding antibiotic use at
HUG was implemented. Some recommendations regarding costly anti-
biotics were provided; restriction was, however, rare. Moreover, at the
pharmacy level, refusal to dispense a drug was uncommon and phys-
icians could prescribe any antimicrobial agent available at HUG.11 In
the outpatient setting there was equally no restriction.
Data collection
Antimicrobial consumption in the hospital
Monthly aggregated data of all antimicrobial drugs delivered within HUG
were provided by the pharmacy department from January 2000 to
December 2007. Long-term care units and the psychiatry department
were excluded, due to their low antibiotic use and high number of
patient-days, which would have diluted antibiotic usage data. In
addition, paediatric wards were excluded since antibiotic use cannot be
measured appropriately in defined daily doses (DDDs) in this setting.12
Following the WHO’s recommended metric, the DDD, i.e. the assumed
average maintenance dose per day for a drug used for its main indication
in an adult, antibiotic usage was expressed as monthly aggregated DDDs
according to the 2007 ATC classification and normalized per 1000
patient-days (antibiotic use density).13
Antimicrobial consumption in the community
The outpatient database used in this study was constructed from pre-
scription files of the OFAC, which serves as an administrative intermediary
between Swiss pharmacists and health insurance companies. OFAC pre-
scriptions cover 92% of all prescriptions filled and 80% of the insured
population in the canton of Geneva. All protected patient information
was removed to create anonymous datasets in accordance with Swiss
data protection regulations. Antibiotic use was expressed as monthly
aggregated DDDs, normalized per 1000 inhabitants.
Bacterial isolates
The microbiology laboratory of HUG provided monthly aggregated data
from January 2000 to December 2007 on the number of incident clinical
E. coli isolates. All isolates are routinely tested for resistance to ciproflox-
acin, trimethoprim/sulfamethoxazole and cefepime using the disc
diffusion method. Results are interpreted according to CLSI criteria.14
Geneva surrounding community setting: population of  453 000 inhabitants. Outpatient prescriptions are
systematically recorded by OFAC, covering 92% of all prescriptions filled and 80% of the insured population in
the canton of Geneva.
HUG setting: primary and tertiary care teaching hospital in Switzerland with 2200 beds. Long-term care units
and paediatric and psychiatry departments were excluded from this analysis. Infection control programme with
one director, three associate hospital epidemiologists and nine full-time infection control nurses.    
Population characteristics: mean hospitalization days, 51 524 per month (range 48 102–55 128); 850 000
outpatient visits each year. 
Infection control campaigns during the study: HUG launched two hospital-wide promotion campaigns; 
Vigigerme®  in spring 2003 and ‘Clean care is safer care’ in autumn 2005 (including hand hygiene observation
of healthcare personnel).
Antibiotic use: during the study period there was no institutional antibiotic policy; physicians could prescribe
any antimicrobial agent available at HUG. Beginning in March 2006, HUG experienced a shortage of cefepime
leading to an increase in piperacillin/tazobactam use.  
ESBL screening and isolation policy: systematic on-admission screening of specific patient groups at high risk
of ESBL carriage, i.e. patients formerly known to be ESBL carriers or patients coming from regions with
endemic rates. ESBL carriers underwent contact precautions routinely and were isolated in single rooms
whenever possible.       
Study period: January 2000 to December 2007.
Definition of ESBL: number of incident clinical E. coli isolates resistant to cefepime.
Figure 1. Population, setting, definitions, antibiotic policy, promotion campaigns, infection control interventions and study period.
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The incidence of cefepime resistance in E. coli was considered as a surro-
gate marker for production of ESBL since confirmatory tests for ESBL pro-
duction were introduced only in 2004.15
Isolates resistant to ciprofloxacin, cefepime and trimethoprim/sulfa-
methoxazole obtained ,48 h after admission were defined as commu-
nity associated (CA) and those obtained ≥48 h after admission were
classified as hospital associated (HA). Due to the limited number of
cefepime-resistant isolates no distinction was made between CA and
HA isolates. Incidence density of resistant isolates was expressed as
the number of cultures per 1000 patient-days with the elimination of
duplicates by including only the first E. coli isolate.16 All non-susceptible
isolates (i.e. resistant and intermediate) were considered resistant.
Statistical analysis
Since temporally sequenced observations on antibiotic use and resist-
ance are not independent, applying simple regression analysis would
be inappropriate.17 Therefore, as suggested by the ORION statement,18
we used time-series analysis with autoregressive integrated moving
average (ARIMA) models using the Box–Jenkins method integrating the
stochastic dependence of consecutive data over time.19 We developed
five different models to analyse the association between antibiotic use
and resistance in CA and HA isolates of E. coli, focusing on the link with
ciprofloxacin, cefepime and trimethoprim/sulfamethoxazole usage.
A linear transfer function modelling method proposed by Lopez-Lozano
was used to quantify the dynamic relationship between antibiotic use
and the incidence of resistant isolates, taking into account possible
time delays (lag times) of up to 5 months.17,19,20
To meet the stationarity requirement (constant mean, variance and
autocorrelation through time), ciprofloxacin resistance in E. coli isolates
and other explanatory variables were logarithmically transformed,
while ESBL data and associated explanatory variables were transformed
by first-order differentiation. Trimethoprim/sulfamethoxazole resistance
in E. coli did not need any transformation.
For each individual series, we fitted an ARIMA model according to
Box–Jenkins methodology and performed the following steps.19 We
first checked whether the series needed to be differentiated [i.e.
whether the parameter ‘d’ equals 0, 1 or 2 in the ARIMA (p,d,q) model]
with the augmented Dickey–Fuller test. We then created the model by
determining the values of the remaining parameters ‘p’ and ‘q’ of the
ARIMA (p,d,q) model with the autocorrelation (ACF) and partial autocor-
relation (PACF); subsequently, we estimated model parameters by an
unconditional least squares method; and finally checked the adequacy
of the model, i.e. the residuals to be ‘white noise’ (Ljung–Box statistic),
and statistical significance of the parameters at a P value of ,0.05.
After obtaining the univariate ARIMAmodels, we identified the transfer
function model from the cross-correlation function estimating the corre-
lations between the antibiotic use series at different time lags and the inci-
dence of resistant CA and HA isolates. We then estimated the transfer
function model. Significance tests for parameter estimates at a P value
of,0.05 were used to eliminate the unnecessary terms. Among different
models we chose the most parsimonious one, i.e. the model with the
fewest parameters and highest biological plausibility. All final model
residuals passed a ‘white noise’ test (based on Ljung–Box statistics). For
each model, the R2 coefficient was calculated as goodness-of-fit
measure, expressing the fraction of the variance of the dependent variable
explained by the dynamic regression model. All statistical analyses were
performed with EViews 6 software (QMS, Irvine, CA, USA).
Results
Antibiotic use in both settings
Monthly rates of antimicrobial use in the canton of Geneva and
at HUG from January 2000 to December 2007 are detailed in
Table 1. In the outpatient setting average antimicrobial use
over the study period was 14.2 DDDs/1000 inhabitants with a
positive upward trend (P¼ 0.0061). Penicillins were the most
widely used antibiotic class (34%; pooled rate, 4.87 DDDs/1000
inhabitants), followed by fluoroquinolones, macrolides, cephalos-
porins and trimethoprim/sulfamethoxazole.
At HUG, average antimicrobial use over the study period was
550 DDDs/1000 patient-days with a positive upward trend (P¼
0.0114). In this setting, penicillins were also the most widely
used antibiotic class (161 DDDs/1000 patient-days), followed
by cephalosporins and carbapenems (151 DDDs/1000 patient-
days) and fluoroquinolones (76 DDDs/1000 patient-days).
Incidence and dynamic regression of ciprofloxacin
resistance in E. coli
A significant increase in the incidence of CA ciprofloxacin-
resistant E. coli isolates (4.8% in 2000 to 14.6% in 2007; P,
0.0001) and HA ciprofloxacin-resistant E. coli isolates (7% in
2000 to 16.7% in 2007; P, 0.0001; R2¼ 0.20) was observed
(Table 2 and Figure 2). The average monthly incidence was
0.31 (range 0–0.91) for CA ciprofloxacin resistance and 0.44
(range 0.15–0.84) for HA ciprofloxacin resistance in clinical iso-
lates per 1000 patient-days. For the CA ciprofloxacin-resistant
isolates, we identified an ARIMA model with one significant auto-
regressive term of order 1 and one significant moving average
term order 1 (R2¼ 0.31); the HA ciprofloxacin resistance model
had one significant autoregressive term of order 1 (R2¼ 0.14).
The transfer function model of CA ciprofloxacin resistance
explained 51% of the variation in incidence (Table 3). In this
model, two statistically significant explanatory variables were
identified, outpatient ciprofloxacin and moxifloxacin usage,
whereas outpatient norfloxacin, levofloxacin and ofloxacin use
was not statistically significant. For example, an increase of 1%
in ciprofloxacin use would generate an immediate increase of
1.28% in the number of CA ciprofloxacin-resistant isolates and
an additional 0.97% 1 month later.
The transfer function model of HA ciprofloxacin resistance
explained only 18% of the incidence of HA resistance (Table 3).
Outpatient ciprofloxacin use was identified as the only statisti-
cally significant explanatory variable. According to this model
an increase of 1% in community ciprofloxacin use would be fol-
lowed by an increase 1 month later of 0.74% in HA ciprofloxacin-
resistant E. coli isolates.
Incidence and dynamic regression of cefepime
resistance in E. coli
The monthly average incidence of resistance to cefepime in
E. coli was 0.15 (range 0–0.41) clinical isolates per 1000 patient-
days. Regarding the incidence of cefepime resistance, we ident-
ified an ARIMA model (1,1,0) after first-order differentiation
with an autoregressive term of order 1 (R2¼ 0.15). The transfer
function model (R2¼ 0.51), yielded statistically significant
effects of inpatient use of ceftriaxone, ciprofloxacin, cefepime
and piperacillin/tazobactam, as well as outpatient use of cipro-
floxacin, on the incidence of cefepime-resistant E. coli isolates
(Table 4). An increased hospital usage of 1 DDD of the following
antibiotics would time-dependently raise the cefepime resist-
ance rate to different extents (Table 4). For instance, the
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Table 1. Quantity and trends of antibiotic use in the canton of Geneva and at HUG, January 2000 to December 2007
WHO
classification Antimicrobial use
Surrounding community HUG
average monthly
use (min–max)a
% of
J01
use trend P
average monthly
use (min–max)b
% of
J01
use trend P
J01 total antibiotic use 14.22 (8.6–19.77) 100 upward 0.0061 550 (456–622) 100 upward 0.0114
J01C amoxicillin/
clavulanate
3.32 (1.86–5.14) 23 upward ,0.001 94 (63–141) 17 downward 0.04
amoxicillin 1.55 (0.85–2.39) 11 upward ,0.001 62 (39–96) 11 no 0.1214
piperacillin/
tazobactam
0 0 4.6 (0–18.3) 1 upward ,0.001
J01D cefazolin 0 0 8.4 (3.3–17.2) 2 downward ,0.001
second-generation
cephalosporins
1.3 (0.56–2.9) 9 downward ,0.001 40 (26.3–61.2) 7 upward ,0.001
third-generation
cephalosporins
0.61 (0.23–1.09) 4 upward ,0.001 52.1 (29.2–72.8) 10 upward ,0.001
cefepime 0 0 25.1 (0–41.3) 5 downward ,0.001
carbapenems 0 0 25.5 (16.2–45) 5 upward 0.0029
J01M fluoroquinolones 2.6 (1.77–3.25) 18 upward ,0.001 76.4 (49.3–100.4) 14 no 0.5057
ofloxacin 0.1 (0.06–0.16) 1 no 0.5776 3.3 (0.3–7.7) 1 no 0.05071
ciprofloxacin 1.24 (0.87–1.73) 9 upward ,0.001 47.7 (30.8–66.8) 9 upward 0.0254
norfloxacin 0.7 (0.53–0.86) 5 upward ,0.001 13.6 (6.2–23.5) 3 downward ,0.001
levofloxacin 0.26 (0.11–0.54) 2 downward ,0.001 20.3 (1.5–21.9) 2 no 0.1032
moxifloxacin 0.28 (0–0.54) 2 upward ,0.001 1.5 (0–6.5) 0 upward ,0.001
J01FA macrolides 2.13 (1.02–3.95) 15 no 0.5004 38.6 (18.7–80) 7 no 0.2035
J01EE01 trimethoprim/
sulfamethoxazole
0.4 (0.28–0.55) 3 downward ,0.001 16.6 (6.7–24.8) 3 upward 0.0103
J01XA glycopeptides 0 0 16.1 (7.3–25.6) 3 no 0.6961
aQuantities of antimicrobials expressed in DDDs per 1000 inhabitants.
bQuantities of antimicrobials expressed in DDDs per 1000 patient-days.
Table 2. Percentages of non-duplicate clinical isolates of E. coli resistant to ciprofloxacin, trimethoprim/sulfamethoxazole and cefepime (n); data
from the Microbiology Laboratory, HUG, January 2000 to December 2007
Antibiotic resistance to Total 2000 2001 2002 2003 2004 2005 2006 2007
P for
trend
Ciprofloxacin total 10.9 (2097) 6.0 (134) 7.9 (191) 9.4 (241) 11.9 (315) 10.4 (245) 12.8 (271) 13.6 (332) 15.4 (368) ,0.0001
Ciprofloxacin (CA) 9.4 (970) 4.8 (50) 6.1 (46) 6.8 (102) 9.3 (135) 8.8 (121) 10.4 (135) 11.3 (171) 14.6 (215) ,0.0001
Ciprofloxacin (HA) 12.8 (1123) 7.0 (84) 8.7 (145) 12.9 (140) 15.2 (180) 12.8 (124) 16.4 (136) 17.2 (161) 16.7 (153) ,0.0001
Trimethoprim/
sulfamethoxazole total
23.9 (4780) 23.7 (549) 24.5 (611) 21 (554) 23.3 (639) 23.8 (576) 24.4 (593) 24.5 (610) 25.8 (648) 0.2753
Trimethoprim/
sulfamethoxazole (CA)
21.5 (2484) 21.3 (265) 20.7 (247) 19.4 (302) 21.5 (336) 22.2 (317) 21.7 (321) 22.3 (340) 23.2 (356) 0.2198
Trimethoprim/
sulfamethoxazole (HA)
27 (2296) 26.5 (284) 28 (364) 23.3 (252) 25.9 (303) 26.1 (259) 28.6 (272) 28 (270) 29.8 (292) 0.3674
Cefepime total 1.9 (289) 1.39 (3) 1.37 (4) 0.92 (24) 1.44 (38) 1.34 (32) 2.11 (50) 2.51 (60) 3.22 (78) 0.0098
Total¼ aggregated data for CA and HA resistant isolates.
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resistance rate would increase immediately by 0.0041 after
increased ceftriaxone usage, and by 0.0043 1 month after
increased in-hospital usage of ciprofloxacin and an additional
0.0045 after 5 months.
Incidence and dynamic regression of resistance
in E. coli to trimethoprim/sulfamethoxazole
No significant trends in the incidence of trimethoprim/
sulfamethoxazole-resistant CA and HA E. coli isolates were
observed (Table 2 and Figure 2). The average monthly incidence
of CA trimethoprim/sulfamethoxazole resistance was 1.05
isolates per 1000 patient-days (range 0.43–2.08) and 0.97 iso-
lates per 1000 patient-days (range 0.28–1.60) for HA isolates.
No model could sufficiently explain the rate of resistance in
the community. For HA trimethoprim/sulfamethoxazole resist-
ance, the model yielded a very low R2 (0.14). Only outpatient
use of trimethoprim/sulfamethoxazole was identified as a stat-
istically significant variable in this model (lag 4 months; P¼
0.0085).
Discussion
During this study, we observed an increase in fluoroquinolone
resistance among CA and HA isolates of E. coli, with slightly
higher rates in the latter group. This is in line with data from
most other European countries, where a general increase in
fluoroquinolone-resistant E. coli has been observed.7 It is note-
worthy that the rate of ciprofloxacin resistance in E. coli is
approaching the resistance rate of trimethoprim/sulfamethoxa-
zole, an antibiotic that has mostly been abandoned as empirical
therapy for upper urinary tract infections due to the high resist-
ance rate.
We also observed a notable increase in cefepime-resistant
E. coli over the study period, which probably reflects the epide-
miology of ESBL-producing Enterobacteriaceae in our region, as
in the rest of Europe.21 Rates of trimethoprim/sulfamethoxazole
resistance were, however, stable over the study period in both
settings despite a significant decrease in trimethoprim/sulfa-
methoxazole use in the community. This phenomenon has also
been observed in other countries and is possibly related to
co-selection of trimethoprim/sulfamethoxazole resistance by
other antibiotics.22–24 Factors influencing the reversibility of anti-
biotic resistance in the absence of antibiotic pressure are still
incompletely understood.25 Two recent papers also failed to
show a significant association between trimethoprim/sulfa-
methoxazole use and resistance on an individual patient
level.26,27
Our findings confirm the relatively high outpatient antimicro-
bial use (14.2 DDDs/1000 inhabitants) in the canton of Geneva
compared with German-speaking Switzerland.1 The exact
causes of the variation in antibiotic use within Switzerland are
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Figure 2. Monthly incidence of non-duplicate clinical isolates of
ciprofloxacin-, trimethoprim/sulfamethoxazole (co-trimoxazole)- and
cefepime-resistant E. coli isolates per 1000 patient-days. HUG, January
2000 to December 2007. ESBL, ESBL-producing E. coli.
Table 3. Multivariate transfer function model of fluoroquinolone use in both settings and temporal relationship with the incidence of non-duplicate
clinical isolates of E. coli resistant to ciprofloxacin per 1000 patient-days; HUG, January 2000 to December 2007
Variable
CA ciprofloxacin resistance, R2¼0.51 HA ciprofloxacin resistance, R2¼0.18
laga (months) parameterb (SE) t statistic P value laga (months) parameterb (SE) t statistic P value
Constant 21.16 (0.24) 24.94 ,0.0001 20.94 (0.08) 212.31 ,0.0001
Ciprofloxacinc 0 1.28 (0.49) 2.62 0.0104
Ciprofloxacinc 1 0.97 (0.48) 2.00 0.0485 1 0.74 (0.28) 2.65 0.0095
Moxifloxacinc 4 0.43 (0.16) 2.69 0.0088
Autoregressive termd 1 0.30 (0.11) 2.78 0.0068 2 0.27 (0.10) 2.76 0.0069
Moving average terme 8 0.35 (0.11) 3.22 0.0019
aDelay necessary to observe the effect.
bSize and direction of the effect, with variables expressed in logarithms.
cOutpatient use.
dThe autoregressive term represents the past value of the resistance.
eThe moving average term represents disturbances or abrupt changes of resistance.
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unclear, but socioeconomic and cultural factors most likely play
a role.1 Overall antibiotic use is slightly lower than that described
by Filippini et al.1 (15.6 DDDs/1000 inhabitants in 2002), possibly
reflecting the different data sources and classification methods.
As in other European countries, fluoroquinolone use has
increased over the past few years and represented 18% of
total outpatient antibiotic use.7 According to antibiotic prescrib-
ing quality indicators established by the European Surveillance
of Antimicrobial Consumption, this represents excess fluoroqui-
nolone use.28 Unlike antibiotic use in the community, overall
antibiotic use at HUG is comparable to that of other Swiss ter-
tiary care centres.29 Fluoroquinolone use remained relatively
stable, constituting 14% of overall antibiotic use. This also rep-
resents a relatively high use compared with other European
countries, but is much lower than the USA, where fluoroquino-
lones represent the most frequently prescribed antibiotic
class.30,31
We found a correlation between outpatient fluoroquinolone
use and ciprofloxacin resistance, in both CA and HA isolates.
This finding confirms previous data that have shown that
regions with higher fluoroquinolone use have higher rates of
fluoroquinolone-resistant E. coli.7 One of the few studies correlat-
ing community antibiotic use to rates of antibiotic-resistant
microorganisms in hospitals serving these communities also
observed a significant correlation between community fluoroqui-
nolone use and fluoroquinolone-resistant E. coli in 17 hospitals in
the USA.32 Importantly, unlike other studies we did not find a
correlation between fluoroquinolone use in the hospital and
the rate of ciprofloxacin resistance in HA isolates.6,33 This
finding might be explained by the fact that most E. coli detected
in clinical isolates during the hospital stay are part of the
endogenous patient flora and therefore probably of community
origin. Relatively stable fluoroquinolone use in the hospital
during the study period might also have contributed to this
finding. A recently published study has investigated the
relationship between outpatient fluoroquinolone consumption
in a region in south-western France and the incidence of
fluoroquinolone-resistant E. coli between 2004 and 2007 in the
only tertiary-care academic centre in the region.34 Using
similar methods, the researchers found a significant effect of
levofloxacin use in the community with resistant HA E. coli,
albeit with a very long time lag (12 months). In contrast to this
investigation, the strength of our study was that a more com-
plete dataset over a longer time period with better population
coverage was analysed in a smaller, but more homogeneous,
region, yielding biologically plausible findings.
Importantly, we found an association between the incidence
of cefepime resistance in E. coli (indicating ESBL production in
most isolates) and the use of several antibiotic classes in the
hospital (notably ceftriaxone, ciprofloxacin, cefepime and pipera-
cillin/tazobactam) and fluoroquinolone use in the community.
The short time lags for hospital use of ciprofloxacin (lags 1 and
5 months) and ceftriaxone (lag 0) are noteworthy since—as
opposed to time lags of .6 months—they are also biologically
plausible.35 This finding confirms a recent study from Germany
that showed an association between the use of third-generation
cephalosporins and fluoroquinolones and the incidence of noso-
comial ESBL-producing bacteria, however, after a longer time lag
(up to 3 months).20 In addition, several other studies have
observed an association between previous use of cephalosporins
and fluoroquinolones, and infection with ESBL producers in the
outpatient and inpatient settings.8,36 The frequent cross-
resistance observed in ESBL-carrying organisms, which is often
mediated by genes carried in the same mobile genetic elements
as ESBLs, is thought to be responsible for the effect of fluoroqui-
nolone use on ESBL incidence. Outpatient fluoroquinolone use
might be of particular importance with regard to possible inter-
ventions to contain the current epidemic of CTX-M-15-producing
E. coli, a frequent cause of CA urinary tract infection in Europe.37
Our study has several limitations. This study is a single-centre,
retrospective, observational, ecological study using aggregate
data. This design bears the risk of ecological bias, since the use
of individual patient data might give different results.38 DDDs
may not represent true prescription data and may not appropri-
ately reflect antibiotic use in adults with renal impairment and
other co-morbidities.39 DDDs remain, however, the most com-
monly applied unit for measuring antibiotic use, since it allows
internal and external benchmarking. Since our main goal was
to analyse the impact of antibiotic use on resistance, we did
not adjust antibiotic use in the community for the incidence of
flu-like illness as done by other groups, which might be important
when analysing trends over several years.40,41 Although we could
eliminate prescriptions for children from the hospital antibiotic
use data, we were not able to do this for the community data.
Fluoroquinolones are, however, rarely used in children and out-
patient fluoroquinolone data should mostly reflect use in
adults. A further limitation is the fact that we only had access
to microbiological data from the laboratory at HUG and thus
only patients consulting at that hospital were included. Even
though HUG serves also as the major primary care hospital in
the region, the patient population might be slightly different
from the population seen by general practitioners in Geneva.15
Nevertheless, yearly susceptibility data provided by the largest
external microbiology laboratory in Geneva confirm the resist-
ance data observed in CA isolates at our hospital (data not
Table 4. Multivariate transfer function model of antibiotic use in both
settings and temporal relationship with the incidence of non-duplicate
clinical isolates of E. coli resistant to cefepime per 1000 patient-days;
HUG, January 2002 to December 2007; R2¼ 0.51
Variable
Laga
(months) Parameterb (SE) t statistic P value
Ceftriaxonec 0 0.0041 (0.0017) 2.4047 0.0195
Ciprofloxacinc 1 0.0043 (0.0013) 3.2126 0.0022
Ciprofloxacinc 5 0.0045 (0.0014) 3.2045 0.0022
Cefepimec 3 0.0034 (0.0016) 2.1502 0.0358
Piperacillin/
tazobactamc
3 0.0099 (0.0042) 2.3073 0.0247
Ciprofloxacind 4 0.247 (0.0080) 3.0809 0.0032
Autoregressive
terme
1 20.5877 (0.0108) 25.4236 ,0.0001
aDelay necessary to observe the effect.
bSize and direction of the effect.
cHospital use.
dOutpatient use.
eThe autoregressive term represents the past value of the resistance.
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shown). We included only clinical isolates of E. coli in our analysis
and did not include surveillance cultures. We therefore probably
underestimated the incidence of resistance, notably with regard
to ESBL carriage. We used cefepime resistance as surrogate
marker for ESBL production since we did not have reliable data
about confirmatory test results for the entire study period. This
definition might have overestimated ESBL rates. We know,
however, that in our setting cefepime resistance in E. coli is
nearly universally associated with ESBL production. A further
limitation is that we did not type isolates or assess mechanisms
of fluoroquinolone resistance, which might change over time and
thus modify the impact of fluoroquinolones on resistance
selection.42,43
Despite these limitations, we believe that this study is valu-
able since it combines longitudinal data over several years
from a distinct metropolitan area and the only major public hos-
pital in the same area. By using appropriate statistical methods,
our study provides further evidence that antibiotic use in the
community influences resistance rates in hospital (spill-over
effect). We were also able to confirm the influence of inpatient
and outpatient antibiotic use, notably fluoroquinolones and
third-generation cephalosporins, on ESBL-producing E. coli.
Controlling antibiotic resistance has proved to be far more dif-
ficult than its creation and selection. Nevertheless there is some
evidence that antibiotic resistance can be controlled by reducing
unnecessary antibiotic use.44 A recently published retrospective
study from Israel showed that reduction in ciprofloxacin use in
the community in the context of a restriction policy was associ-
ated with a concomitant increase in susceptibility to ciprofloxa-
cin in E. coli from urinary isolates.45 Our results are in line with
previous studies and confirm the impact of fluoroquinolone use
in the inpatient and outpatient setting on resistant E. coli.
Efforts to substitute fluoroquinolones for certain indications
with antibiotics with less ecological impact such as nitrofuran-
toin or fosfomycin for urinary tract infections should continue.
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